NewAmsterdam Pharma Co N.V. (NAMS) Market Cap & Valuation Ratios
NewAmsterdam Pharma Co N.V. (NAMS) has a market cap of $2.4B and a price-to-sales ratio of 330.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAMSNewAmsterdam Pharma Co N.V.Follow NAMS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NAMS | 2.4 | — | 241.9 | — | -6.1% | -89% | — | -116% |
| ABCL | 3.6 | — | 53.0 | — | -3.3% | +101% | -340% | -27% |
| OGN | 3.6 | 17.6 | 1.8 | 8.4 | 15.7% | -2% | 16% | 5% |
| ZLAB | 2.7 | — | 5.2 | — | -5.2% | +5% | -59% | -112% |
| HCM | 2.5 | 143.6 | 2.2 | — | 0.4% | -9% | -6% | -3% |
| BHC | 2.4 | — | 2.0 | 10.4 | — | +10% | 8% | 4% |
| BRVE | 1.9 | — | — | — | — | — | — | — |
| GENB | 1.6 | — | — | — | — | — | — | — |
| QURE | 1.6 | — | 42.6 | — | -10.4% | +30% | — | — |
| CMPS | 1.5 | — | — | — | — | — | — | — |
| GPCR | 1.5 | — | — | — | -14.9% | — | — | -30% |
| Median of these 10 | 80.6 | 3.7 | 9.4 | -4.2% | +8% | -6% | -15% |
; EV/Sales 241.9 vs. 3.7.
Growth vs. price
each dot a company · hover or tap for valuesNewAmsterdam Pharma Co N.V. — questions
- What is NewAmsterdam Pharma Co N.V.'s market cap?
- $2.4B.
- What is NewAmsterdam Pharma Co N.V.'s price-to-sales ratio?
- 330.9.
Every figure on this page comes from NewAmsterdam Pharma Co N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.